PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 3

Completed

• Conditions: Multiple Myeloma

• Registration Number: NCT00048230
• Lead Sponsor: Millennium Pharmaceuticals, Inc.

Brief Summary

This study will compare the efficacy of PS-341 versus high dose dexamethasone.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-06
• Study First Submitted: 2002-10-28
• Study First Submitted QC: 2002-10-29
• Study First Posted: 2002-10-30
• Primary Completion: 2004-07
• Study Completion: 2004-12
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-12
• Last Update Posted: 2012-01-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 620

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (93)

Alta Bates Comprehensive Cancer Center; 🇺🇸 Berkeley, California, United States

City of Hope; 🇺🇸 Duarte, California, United States

Scripps Clinic; 🇺🇸 La Jolla, California, United States

Loma Linda University Medical Center; 🇺🇸 Loma Linda, California, United States

Kaiser Permanente Oncology Clinical Trials; 🇺🇸 Vallejo, California, United States

Lombardi Cancer Center, Georgetown University Medical Center; 🇺🇸 Washington, District of Columbia, United States

Med Star Institute, Washington Cancer Center; 🇺🇸 Washington, District of Columbia, United States

Hematology/Oncology Associates, PA; 🇺🇸 Jacksonville, Florida, United States

University of Miami; 🇺🇸 Miami, Florida, United States

H. Lee Moffitt Cancer Center, University of S. Florida; 🇺🇸 Tampa, Florida, United States

Scroll for more (83 remaining)